Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Amicus Therapeutics Inc. buy Guggenheim

Amicus Therapeutics Inc.
Start price
€10.20
07.11.24 / 50%
Target price
€13.91
07.11.25
Performance (%)
-25.49%
End price
€7.60
08.11.25
Summary
This prediction ended on 08.11.25 with a price of €7.60. The prediction for Amicus Therapeutics Inc. disappointed with a performance of -25.49%. Guggenheim has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Amicus Therapeutics Inc. - - -
iShares Core DAX® 1,84 % 1,39 % 8,65 %
iShares Nasdaq 100 4,66 % -1,80 % 27,82 %
iShares Nikkei 225® 3,96 % -5,22 % 51,81 %
iShares S&P 500 3,70 % 1,58 % 24,09 %

Comments by Guggenheim for this prediction

In the thread Amicus Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -25.49%
Target price 13.914
Change
Ends at 07.11.25

Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for FOLD provided by MarketBeat

Guggenheim 
0
Report Share
07.11.24
In the thread Trading Amicus Therapeutics Inc.
Prediction Buy
Perf. (%) -25.49%
Target price 13.914
Change
Ends at 07.11.25

Die von Guggenheim gewählte maximale Laufzeit wurde überschritten

Guggenheim 
0
Report Share
08.11.25